MediWound to Present at the H.C. Wainwright 26th Annual Global Investment Conference
03 sept. 2024 08h00 HE
|
MediWound Ltd.
YAVNE, Israel, Sept. 03, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced that Ofer Gonen, Chief...
MediWound Announces U.S. Food and Drug Administration Approval of NexoBrid® for the Treatment of Pediatric Patients with Severe Thermal Burns
15 août 2024 16h15 HE
|
MediWound Ltd.
YAVNE, Israel, Aug. 15, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced that the U.S. Food and...
MediWound Reports Second Quarter 2024 Financial Results and Provides Company Update
14 août 2024 07h00 HE
|
MediWound Ltd.
Completed Construction of New NexoBrid® Manufacturing Facility €16.25 Million EIC Funding Expedites EscharEx® Development for Diabetic Foot Ulcers, Significantly Expanding the Addressable...
MediWound Announces Positive Results from the U.S. NexoBrid® Expanded Access Protocol (NEXT)
05 août 2024 07h30 HE
|
MediWound Ltd.
YAVNE, Israel, Aug. 05, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced the positive results of...
MediWound to Report Second Quarter 2024 Financial Results
02 août 2024 08h00 HE
|
MediWound Ltd.
YAVNE, Israel, Aug. 02, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced that the Company will...
MediWound Announces Publication of the EscharEx® Phase II ChronEx Study Results for Venous Leg Ulcers
29 juil. 2024 08h00 HE
|
MediWound Ltd.
Research Published in THE LANCET's eClinicalMedicineEscharEx® Outperforms Non-Surgical Standard of Care in Debridement and Promotion of Healthy Granulation Tissue YAVNE, Israel, July 29, 2024 ...
MediWound Announces €16.25 Million Funding from the European Innovation Council Accelerator Program
16 juil. 2024 07h30 HE
|
MediWound Ltd.
Funds to be used for clinical development of EscharEx® to treat diabetic foot ulcers (DFUs) Award advances MediWound’s DFU program and its future revenues four years ahead of original schedule ...
MediWound Announces $25 Million Strategic Private Placement Financing
15 juil. 2024 07h00 HE
|
MediWound Ltd.
YAVNE, Israel, July 15, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the world leader in next-generation enzymatic therapeutics for tissue repair, today announced it has entered into a...
MediWound Reports First Quarter 2024 Financial Results and Provides Company Update
29 mai 2024 07h00 HE
|
MediWound Ltd.
NexoBrid® interest surges; $5 million in Q1 2024 revenue, with $24 million forecast for the year Manufacturing facility on target for completion by mid-2024 EscharEx® Phase III study to launch 2H...
MediWound to Report First Quarter 2024 Financial Results
22 mai 2024 08h00 HE
|
MediWound Ltd.
YAVNE, Israel, May 22, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced that the Company will...